Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)
Previous Close
$8.13
52W Range
$4.71 - $9.74
50D Avg
$7.29
200D Avg
$6.07
Market Cap
$1.15B
Avg Vol (3M)
$1.23M
Beta
1.46
Div Yield
-
AUPH Company Profile
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
AUPH Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TGTX | TG Therapeutics, Inc. |
| SRPT | Sarepta Therapeutics, Inc. |
| EXEL | Exelixis, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| PTCT | PTC Therapeutics, Inc. |
| AXSM | Axsome Therapeutics, Inc. |
| BTAI | BioXcel Therapeutics, Inc. |
| MCRB | Seres Therapeutics, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |